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SUMMARY
Naturally acquired immunity to malaria requires repeat infec-
tions yet does not engender sterile immunity or long-lasting
protective immunologic memory. This renders infants and
young children the most susceptible to malaria-induced mor-
bidity and mortality, and the ultimate target for a malaria
vaccine. The prevailing paradigm is that infants initially gar-
ner protection due to transplacentally transferred anti-malar-
ial antibodies and other intrinsic factors such as foetal
haemoglobin. As these wane infants have an insufficient
immune repertoire to prevent genetically diverse Plasmodium
infections and an inability to control malaria-induced immu-
nopathology. This Review discusses humoral, cell-mediated
and innate immune responses to malaria and how each con-
tributes to protection – focusing on how deficiencies in infant
and paediatric immune responses might influence malaria vac-
cine efficacy in this population. In addition, burgeoning evi-
dence suggests a role for inhibitory receptors that limit
immunopathology and guide the development of long-lived
immunity. Precisely how age or malaria infections influence
the function of these regulators is unknown. Therefore the
possibility that infants may not have the immune-dexterity to
balance effective parasite clearance with timely immune-
regulation leading to protective immunologic memory is con-
sidered. And thus, malaria vaccines tested in adults and older
children may not be predictive for trials conducted in infants.
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INTRODUCTION
We often reduce, into a single sentence, the accumulation
of decade’s worth of clinical and epidemiologic studies on
malaria with an estimated number of cases and of children
each year who die. We all agree that events leading to the
manifestations of severe malaria in a paediatric population
are multi-factorial and are influenced by intrinsic as well as
extrinsic factors. These include, but are not limited to,
malaria transmission intensity, parasite genetic diversity
and complexity of infection, the degree of maternal anti-
body protection and prenatal malaria experience, foetal
haemoglobin, haemoglobin S heterozygosity, and nutri-
tional status. These factors aside, children remain more
susceptible to malaria compared to adults. This age-associ-
ated susceptibility has in part been explained by children
being immunologically na ve whereby repeat infections are
required to develop a repertoire of immune cells capable of
recognizing the various and antigenically variant malaria-
derived proteins. Once infected, however, children are more
likely to succumb to the immunopathology associated with
malaria [reviewed in (1)] which is primarily the result of
insufficient modulation of TNF-a mediated pro-inflamma-
tory responses induced by parasite molecules and antigens
that stimulate innate and adaptive immunity [reviewed in
(2,3)]. Compounding the complexity of the host–parasite
interaction is the fact that natural malaria infections do
not confer long-lasting protective (i.e. sterile) immunity.
This is illustrated by repeat though less severe infections
present in adults and the waning of immunity after leaving
a malaria endemic area – hence the terms ‘semi-immune’
or ‘partial-protection’ are used when referring to immunity
developed under natural exposure conditions. How the
malaria parasite prevents the acquisition of immunologic
memory remains unresolved; however, possible mecha-
nisms will be discussed in this review.
To better understand age-associated differences in
anti-malarial immunity, immuno-epidemiologic studies of
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the express purpose of discovering which immune media-
tors may be responsible for semi-protective immunity that
could be enhanced or sustained with a malaria vaccine.
What immune responses do asymptomatic malaria-
infected people possess compared to those who have
symptomatic infections? And by extension, which immune
responses confer the semi-immune status benefiting adults
that are lacking in infants and young children? This review
highlights humoral, cell-mediated and innate immune
responses to malaria under natural exposure conditions
that may contribute to the development of protection –
focusing on how ‘deficiencies’ in infant and paediatric
immune responses might influence malaria vaccine efficacy
in this population. Within this context, malaria vaccines
that have shown promise in children will be discussed. As
this review concludes, a better understanding of infant
immunity is needed in order to design an efficacious
malaria vaccine that accomplishes what natural infections
do not.
HUMORAL IMMUNITY
The most compelling evidence that antibodies are impor-
tant for protection against malaria arose from experiments
in the 1960s where passive transfer of sera from semi-
immune adults was used to treat children with clinical
Plasmodium falciparum (Pf) malaria (4,5). Several recent
reviews have summarized what we know about the age-
and exposure-dependent development of naturally
acquired humoral immunity to multiple malaria antigens
that subsequently have been selected as vaccine candidates
(6–9). Antibodies against blood stage malaria proteins are
viewed as the primary mediators that prevent infection –
based on the principle that if antibodies prevent
merozoites from invading red blood cells there will be no
ensuing pathology. However, cross-sectional sero-epidemio-
logic studies to identify precisely which anti-malarial
antibodies mediate resistance to infection have led to con-
flicting results and have failed to reveal easily measurable
correlates of protection. Furthermore, it has been sug-
gested that antibodies may be more indicative of malaria
exposure history in endemic areas rather than representa-
tive of a protective response (10).
More complex study designs in malaria endemic areas
have consequently been undertaken. These studies involve
longitudinal cohorts of children that prospectively
document incidence of infection and number of clinical
episodes of malaria to determine if naturally acquired
immunity to a specific antigen or set of antigens correlates
with protection. This type of study design can also address
the question of cross-protection where primary infection
with one antigenic variant confers protection against infec-
tion with a different variant of the same protein. With this
in mind, more comprehensive sero-surveys using micro-
array technology that simultaneously measure a panel of
antibody titres to multiple and variant malaria antigens
from an extremely small sample volume, have been used to
generate a ‘sero-reactivity profile’ for each individual (11).
Consistent with classic antibody assays, increasing magni-
tude and complexity of antibody repertoires were associ-
ated with malaria exposure and a subsequent decrease in
the incidence of malaria infections (7,11). However, clus-
tering analysis revealed that children with antibodies
against apical membrane antigen 1 (AMA-1) and merozo-
ite surface protein 2 (MSP-2) allelic variants, and MSP-1
block 2 were more likely to have asymptomatic infections
compared to children with very little reactivity or those
who had antibodies against the majority of antigens tested
(11). This suggests that antibody repertoires are both
quantitatively and qualitatively different in children after
the same exposure, and that more antibodies to more anti-
gens are not necessarily more protective. This also sup-
ports the theory that ‘blocking’ antibodies that prevent
the function of another antibody can develop in some
individuals as an immune evasion strategy (12,13) and
emphasizes the need for functional antibody assays and
thoughtful design of malaria vaccine antigens. By extend-
ing the analysis of longitudinal sero-reactivity profiles, the
kinetics of the antibody-parasite interaction could be used
to determine the rate of parasite clearance and the dura-
tion of high titer antibody levels which might provide clues
as to the importance of antibody avidity as well as speci-
ficity in protection. This concept was explored by Filipe
et al. (14) using mathematical modelling. These models
suggested that clinical immunity developed early in life
and was exposure-dependent, while anti-infection immu-
nity developed later in life and was governed by age-
dependent biological processes rather than magnitude of
exposure. Temporal stability of a panel of anti-malarial
antibodies and differential rates of acquisition have yet to
be empirically determined in naturally exposed children,
but this model is intriguing in that the anti-infection
immune profile was dependent on age rather than
cumulative exposure. Sero-profiling has given us a more
comprehensive picture illustrating the development of an
anti-malarial antibody repertoire in young children yet
falls short at revealing how a ‘good’ antibody response is
induced and maintained and why children do not consis-
tently make one.
Another area that is being given more consideration in
malaria vaccine design strategies is IgG subclass switching.
An argument can be made for engineering a malaria
vaccine to preferentially induce IgG3 antibodies that have
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tion of parasite growth (15) and associated with the acqui-
sition of clinical immunity (16). However, little is known
about factors that induce class switching and how the rela-
tive proportion of IgG1⁄IgG3 to different malaria anti-
gens is established. Although class switching appears to be
influenced by intensity of antigen stimulation and the age
of the individual, young children appear to be deficient in
promoting IgG3 production (17). There are also reports
that even when children produce IgG1 and IgG3 antibod-
ies to merozoite antigens they decay rapidly (18).
The maintenance of serum antibody levels after expo-
sure to antigen, either by infection or immunization, has
been referred to as ‘serologic memory’ (19). The mecha-
nisms mediating the development of short-lived antibody
secreting cells and long-lived plasma cells are not fully
understood. However, it appears that short-term serologi-
cal memory may be dependent on antigen stimulation
whereas long-term serological memory is antigen-indepen-
dent and depends on homeostatic activation. Several
mechanisms involved in plasma cell differentiation and
survival have been described, such as B-lymphocyte-
induced maturation protein 1 (Blimp1) and A proliferation
inducing ligand (APRIL). Blimp1 acts in a concentration-
dependent manner to regulate antibody secreting cell
differentiation into short- or long-lived plasma cells (20);
whereas APRIL, along with other transcription factors,
stimulates B-cell proliferation and survival (21). It has yet
to be determined if transcriptional control of activated
B-cell differentiation and survival is influenced by age or
malaria infections. Nonetheless, the notion of short- as
opposed to long-lived antibody secreting cells that serve
different functions and are preferentially induced early in
childhood could explain the counter-intuitive inverse asso-
ciation between age and merozoite inhibition assays
observed in two independent studies of naturally exposed
children (22,23). Growth-inhibitory assays are an in vitro
functional means to determine if antibodies found in an
individual’s plasma can prevent a merozoite from invading
an erythrocyte (22). These assays are malaria specific but
do not reveal which anti-malarial antibodies prevent mero-
zoite invasion. In contrast to an overall increase in total
IgG antibody titres to most blood stage malaria antigen,
the magnitude of in vitro growth-inhibitory antibody
(GIA) activity decreased with age (children screened were
2–14 years old), even though GIA activity was signifi-
cantly associated with less risk of malaria infection after
adjusting for age (22,23). It is possible that single or few
malaria infections may generate low-complexity ‘mono-
specific’ short-lived plasma B cells directed against selected
antigenic domains of merozoite ligands that are function-
ally critical to invasion, akin to the situation when
malaria-na ve individuals are vaccinated with single candi-
date antigens (24,25). These B cells may not receive the
proper signals to be retained in the long-term memory
pool. Studies failing to show protective associations with
GIA activity examined children older than 3 years of age
and adults from malaria endemic areas (26,27). Thus,
these data further support an age-dependent regulation of
B-cell differentiation and survival mechanisms to malaria
antigens when first experienced early in life.
To determine how much growth-inhibitory activity could
be attributed to a single antibody specificity, another in vitro
functional antibody assay was developed (28). MSP-1 is the
most abundant protein on the surface of blood stage Pf mer-
ozoites. This protein induces high titre total IgG antibodies
against the conserved C-terminal MSP-1 19 kDa (MSP-119)
region encoding the B-cell epitopes that are associated with
protection against infection and disease (29–31). Given
these properties, MSP-1 is being tested as a vaccine
candidate (32,33). The in vitro MSP-119 invasion inhibitory
antibody (MSP-119 IIA) assay utilizes transgenic parasites
differing only in their MSP-119 domain and by comparison
of activity in parallel cultures can attribute inhibition to
antibodies solely against MSP-119 (28). Paradoxical results
have been reported for MSP-119 IIA whereby IIA activity
was not associated with protection from infection, was very
low in asymptomatic malaria-exposed individuals, and did
not appear to differ with age (34; Moormann AM, Chelimo
K, Dent AE, et al, unpublished data). However, MSP-119
IIA activity was found to be more prevalent during episodes
of acute febrile malaria compared to healthy age-matched
children from the same malaria holoendemic area (Dent
and Moormann, unpublished data); was associated with
protection from infection in a highland area where malaria
infections are more likely to be symptomatic (35,36);
increased during early infancy (6–24 months of age), and
was associated with prenatal exposure to malaria (37).
Taken together, a possible interpretation is that MSP-119
generates relatively short-lived antibody secreting cells that
are dependent on antigen exposure and may reach levels
sufficient to confer clinical immunity if accompanied by
fever – which will be explored in more detail within the
scope of innate immune priming of adaptive immunity. By
comparison, combined anti-malarial antibody activity
measured by GIA is composed of longer-lived plasma cells
(relative to MSP-119 activity alone) that appear to survive
in the absence of antigen and play a role in protection
from re-infection. The observation that overall functional
anti-malarial antibody activity decreases with age may be
countered by the development of more efficient cell-medi-
ated adaptive immunity, in keeping with the concept that
different components of ‘protective immunity’ may vary
with age.
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recently been reviewed. However, a lack of consensus
remains regarding whether the malaria parasite somehow
prevents the development and⁄or maintenance of long-
lived plasma cells and memory B cells. Yet there is agree-
ment in that children consistently make poorer responses
compared to adults (38). Few studies have directly exam-
ined malaria-specific memory B cells in children as these
assays require a considerable number of lymphocytes and
are more challenging to carry out. One such study con-
cluded that a significant proportion of antibodies to
AMA-1 and cysteine-rich interdomain region 1a
(CIDR1a), a parasite-derived erythrocyte membrane
protein, existed in the absence of cognate memory B cells.
In contrast, MSP-119 specific memory B cells were not
producing antibodies in asymptomatic individuals (39).
The authors speculated that MSP-119 specific memory B
cells may be stimulated to produce anitbodies upon rein-
fection. However, another group went on to further char-
acterize memory CD19
+ B cells in malaria-infected
children from Mali and found a significant proportion
with an ‘exhausted’ phenotype (Weiss and Crompton, per-
sonal communication) compared to individuals from non-
endemic areas. A general definition of an exhausted
lymphocyte is one that is antigen-experienced, has under-
gone some differentiation but is no longer functional. This




lo) found in malaria-experienced chil-
dren expressed an inhibitory receptor Fc-receptor-like-4
similar to those described in HIV-infected individuals who
undergo persistent antigen stimulation (40). Poor antibody
responses may therefore be the results of prematurely
exhausted B cells. Another study examining B-cell subsets
in malaria-exposed Kenyan children provides additional
evidence that malaria infections influence the rate of B-cell
maturation and homeostasis. During acute malaria infec-
tions, there is an overall decrease in total CD19
+ periph-
eral B-cell populations, yet further delineation of B-cell
subsets demonstrates a transient increase in the proportion
of CD38
+ IgD-memory B cells (41,42). Lymphopenia and
hypergammaglobulinaemia have long been recognized as
complications of acute malaria in children (43,44), yet how
malaria impacts the B-cell compartment is not well under-
stood. Through direct interaction with memory B cells via
the CIDR1a of the Pf erythrocyte membrane protein 1
(45,46), malaria could be driving memory cells toward
plasma cell differentiation and migration back to the bone
marrow. Thus, the concern that parasite-derived mediators
could adversely influence the maintenance of long-lived
humoral immunity to malaria vaccines in chronically
infected populations may be well founded, with children
being particularly susceptible.
Finally, the mechanisms by which anti-malarial antibod-
ies are generated by a vaccine or natural infection are
being considered, especially in paediatric populations.
Age-dependent differences have been described for T-cell
independent (TID) B-cell antibody responses and T-cell
dependent (TD) antibody responses [reviewed in (47)].
During the first year of life, neonates are deficient in TID
B-cell responses and tend to have less robust TD antibody
responses in the absence of repeat stimulation [review in
(48)]. As IFN-c producing CD4
+ T cells have been impli-
cated in protective immunity to both liver and blood stage
infections, an efficacious vaccine for infants and young
children aims to not only induce CD4
+ T cell help but
‘boost’ the level of TID antibody production above that
which occurs during a natural malaria infection to levels
observed for adults.
CELL-MEDIATED IMMUNITY
Cell-mediated adaptive immunity is arguably as important
in protection against malaria as humoral immunity; the
discovery and details of which have been extensively
reviewed by others (8,49,50). Suffice it to say, a pro-
inflammatory response is desirable to clear parasites but
when this response in not appropriately regulated, immu-
nopathology ensues (3). The landmark prospective study
of Javanese transmigrants confirmed that adults develop
semi-protective immunity faster than children even though
adults suffered more severe disease compared to children
during initial malaria episodes (51). This study highlights
the understanding that cumulative exposure alone is not
sufficient for developing semi-protective immunity against
malaria, leading us to examine intrinsic reasons why
young children’s immune responses render them suscepti-
ble to malaria. In addition, this study illustrates the age-
associated difference in immunopathology with children
appearing to be hyporesponsive upon primary infection.
A distinction between immunity that prevents malaria
infections and that which prevents disease continues to
resonate. As severe malaria is associated with sustained
and exaggerated pro-inflammatory responses, the onus
falls on a better understanding of down-regulatory mecha-
nisms that may be insufficiently modulated early in life.
Measuring the network of cell-mediated immune
responses has additional challenges over assays designed to
measure humoral immunity, including ethically justified
limitations in blood sample volume, especially from children
under 5 years of age. Therefore, such studies are sorely lack-
ing in human malaria vaccine trials, especially those con-
ducted in children. However, recent advances in multiplex
technologies have begun to shed light on the full functional
potential of antigen-specific T-cell responses against many
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assays and multiparameter flow cytometry have signifi-
cantly expanded our ability to examine human lymphocyte
populations and their functions. Resources availed for
capacity building and technology transfer in malaria ende-
mic countries have also facilitated more sophisticated inves-
tigations of human cell-mediated immunity.
A plethora of cytokine profiles have subsequently been
revealed, similar to sero-profiles, that give us a broader
picture of cell-to-cell signalling in response to a malaria
infection. This technology has been used to investigate the
kinetics of cytokine responses in a sporozoite challenge
study in malaria-na ve adults (52). Walther et al. reported
considerable variation between individuals during the
course of their malaria infection and thus categorized them
into three groups: those with moderate levels of IFN-c and
IL-10, but no IL-12p70; those with IL-12p70 and high
levels of IFN-c and IL-10; and those that failed to up-reg-
ulate pro-inflammatory cytokines but had the highest
TGF-b levels in response to Pf-infected erythrocytes in vitro.
Pro-inflammatory in vitro recall responses (i.e. IFN-c,
IL-12p70, TNF-a and the ratio of TNF-a to bioactive
TGF-b) were associated with the ability to control parasite
growth (length of time to first detection of 1000 para-
sites⁄mL) after challenge infection. In contrast, higher
ratios of IL-12 or TNF-a to IL-10 were correlated with a
more rapid onset of clinical symptoms (i.e. fever, headache
and malaise). This study clearly demonstrates individual
host differences in the magnitude and quality of cell-medi-
ated immunity despite the same parasite exposure, and
hints at the far-reaching consequences of innate immune
signals in generating protective adaptive immunity. Simul-
taneously measuring the sequence and magnitude of pro-
inflammatory events (i.e. IFN-c, TNF-a and IL-6) in con-
junction with antigen presentation signals (i.e. IL-12 and
IL-18), balanced by down-regulatory cytokines (i.e. IL-10,
TGF-b) within the context of a malaria infection or vac-
cine trials in children would significantly improve our
understanding of immunologic harmonization (or lack
thereof) to specific malaria antigens. Especially if these
children continue to be exposed to natural infections that
may subvert the desired response. Longitudinal repeat mea-
surements of relative cytokine contributions during the
course of a malaria infection also gives us the ability to
determine which down-regulatory mediators are missing,
suboptimal or delayed, and may, by their absence, contrib-
ute to the development of immunopathology, especially in
paediatric populations.
Taking the lead in utilizing and optimizing polychro-
matic flow technology are studies of acute and persistent
viral infections which describe a mosaic of T-cell subsets
associated with immune memory and protection [reviewed
in (53)]. Multiparameter (at least six colours) flow studies
have described four important findings about the quality
and magnitude of T-cell responses: (1) antigen concentra-
tion and duration of T-cell stimulation influence pheno-
typic heterogeneity; (2) multi-functional (i.e. more than
one cytokine being secreted from the same cell) T cells
express more IFN-c per cell than mono-functional T cells;
(3) multi-functional T cells are more likely to differentiate
into long-term memory cells and (4) protective antigen-
specific T-cell receptor repertoires display shared, or
so-called public, specificities; i.e. dominance of particular
clonotypes that recognize the same epitope and are found
in a majority of individuals (53,54). What is not yet
known are which factors, including age, regulate the
induction and maintenance of T cells displaying the dis-
tinct phenotypes associated with protection from severe
disease. It would appear that finite exposure to antigen
such as those seen during acute infection tends to generate
long-lasting memory T cells whereas chronic, persistent
infections induce T-cell exhaustion, anergy or deletion via
apoptosis (55). For children living in endemic areas,
malaria can be an acute or chronic infection with high- or
low-density parasitemia depending on intensity of malaria
transmission, degree of maternal antibody protection, pre-
natal exposure, and access to prompt diagnosis and treat-
ment [reviewed in (56)]. Taking into consideration these
variables, one could then speculate that a child with a
high-density malaria infection may generate many immedi-
ate, short-lived mono-functional effector T cells expressing
only IFN-c yet not differentiating into long-term memory
cells, leaving the child susceptible to repeat infections.
Models for signal-strength dependent T-cell differentiation
support this notion, suggesting that T-cell stimulation has
to be ‘just right’ in order to induce T-cell memory (57–
59). Tangentially, differences in IFN-c intensity from
mono- compared to tri-functional T cells may explain the
discordance observed between enzyme-linked immunosor-
bent spot (ELISPOT) and ELISA assay results to the
same antigen and why the cytokine level measured by
ELISA correlates with protection from infection when the
frequency of IFN-c producing cells specific to MSP-1 does
not (Moormann AM, Chelimo K, Dent AE, et al, unpub-
lished data). If, on the other hand, an individual from an
epidemic-prone region becomes infected after only a few
infectious mosquito bites, this person’s T-cell response
might be similar in quality to an acute viral infection and
generate long-term memory cells. Evidence supporting this
possibility comes from immunologic studies of individuals
from highland areas, where the incidence and prevalence
of malaria infections are extremely low for prolonged
periods of time but who are still able to generate malaria-
specific IFN-c recall responses to pre-erythrocytic and
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tance of identifying antigen-specific T-cell memory pheno-
types (i.e. using memory and differentiation markers) and
effector functions (i.e. cytokine and granzymes⁄perforin)
in response to malaria has begun to be explored in
malaria-na ve volunteers participating in phase I trials of
MSP-1 (62) and in animal models of circumsporozoite sur-
face protein (CSP), the leading pre-erythrocytic stage
malaria vaccine candidate (53).
Compounding the issue of T-cell na vet  is evidence
that neonates are biased in utero against a strong pro-
inflammatory response as a residual effect of having
recently been in the intra-uterine environment [reviewed in
(63)]. This state renders neonates and young children at
risk for infection and impairs their responses to many
vaccines [reviewed in (64)]. Because of the naturally
delayed production of TH1 mediated pro-inflammatory
cytokines (i.e. IL-12 and IFN-c), neonatal immunity is
thought to be ‘suppressed’. However, more recent studies
have shown that neonatal monocytes and antigen-present-
ing cells do express pro-inflammatory and regulatory cyto-
kines (i.e. IL-6, IL-10 and IL-23) and at higher levels than
adults (65–67). In addition, a third, independently differ-
entiated, arm of the adaptive T-cell immune response has
recently been described, TH17 cells [reviewed in (68)].
TH17 cells appear to be an early, sequential response to
pathogens prior to the induction of a TH1o rT H2
response (69). In humans, na ve CD4
+ T cells, after stimu-
lation with IL-1b, IL-6 elicited from activated monocytes
via innate immune pathways (70), secrete IL-17 and
induce pro-inflammatory cytokines (i.e. IL-6, IL-1b and
TNF-a) and chemokines (i.e. IL-8) increasing neutrophil
recruitment to clear extracellular pathogens. TH17 cells
are also stimulated with IL-21 and IL-22 in an autocrine
and paracrine fashion by NK cells (68). Curiously, IL-22
increases acute-phase reactants in hepatocytes (71) and
protects them against acute liver inflammation (72). The
influence of TGF-b on TH17 cell induction may differ in
mice and humans but appears to divert activated T cells
away from TH1, TH2 and TH17 cell differentiation and
toward the induction of FOXP3+ regulatory T cells (iT-
reg). Mouse models have been used to examine these four
T cell subsets during a P. yoelii malaria infection and
found that IL-10 producing Tregs impede parasite clear-
ance (73). Taken together, immune equilibrium could be
mediated between TH17 – Tregs early in life until natural
‘suppressors’ of TH1 immunity have been lifted as an
infant ages. Focusing on the few studies of children, those
with a higher incidence of malaria had higher frequencies
of CD4+ CD25
hi regulatory T cells that prevented the
protective IFN-c responses characteristically observed in
adults who have developed anti-malarial immunity (74).
Without longitudinal repeat measurements it is unclear if
a pro-inflammatory response was at one time induced in
these children or if the down-regulatory response was over
zealous or abnormally sustained and prevented induction
of an IFN-c response. Cord blood studies, used as
surrogates to examine neonatal lymphocytes, have
demonstrated that Tregs are particularly abundant at birth
(75), providing additional evidence that down-regulatory
mechanism may be normally more pronounced during
early infancy.
Another area that has received considerable attention to
explain how chronic viral infections can persist is the
phenomena of T-cell exhaustion, whereby T cells acquire
antigen-specific effector function but gradually become less
functional as the infection progresses. There appears to be a
complex layer of synergist, nonredundant inhibitory recep-
tors involved in the regulation of T-cell exhaustion, such as
programmed death 1 and lymphocyte activation gene-3,
that correlate with severity of infection (76). Preliminary age
structured cross-sectional studies comparing expression
levels of these inhibitory receptors on human T cells show
higher levels of expression in children that are inversely
correlated with age (JE Wherry, personal communication).
This provides a possible mechanism by which infants and
young children normally ‘suppress’ pro-inflammatory T-cell
function that could otherwise induce immunopathology.
These inhibitory receptors have also been implicated in reg-
ulating T-cell differentiation into memory (77,78). However,
it is unknown whether the malaria parasite influences the
expression and function of these inhibitory receptors. It is
possible that children who experience severe manifestations
of malaria are not able to properly regulate these inhibitory
pathways compared to children with similar malaria expo-
sures, but milder symptoms. Comparing the immune
responses of children with mild reactions who are able to
control the infection to the responses of children with severe
reactions may offer clues as to whether inhibitory pathway
function is an essential component of the pediatric immune
response to malaria infection.
Overall, cell-mediated immunity involves the induction
and proliferation of antigen-specific T cells that will clear
the infection by direct cytotoxic killing or by assisting with
the formation of antibodies to mediate parasite clearance.
This is then followed by a contraction phase whereby cer-
tain antigen-specific T cells survive as memory – or not.
Little is known about what regulates the contraction and
differentiation into memory phases of a normal T-cell
response let alone how this process may falter in infants
or how malaria may prevent memory T-cell differentiation
and survival. Important insight into these down-stream
events may lie in the nuances of the innate immune signa-
ture from malaria.
A. M. Moormann Parasite Immunology
552   2009 The Author
Journal compilation   2009 Blackwell Publishing Ltd, Parasite Immunology, 31, 547–559A PIVOTAL ROLE FOR INNATE IMMUNITY
Escalating interest in how innate immune cells and signals
initiate the quality of adaptive immunity has increased our
understanding of immune responses to malaria [reviewed
in 79,80)]. Innate immune lymphocytes capable of
recognizing a pathogen without prior stimulation include
DCs, monocytes, macrophages, NK cells, NK T cells and
gamma-delta (cd) T cells. When DCs or monocytes-macro-
phages encounter a pathogen and release cytokines such
as IL-12, IL-15, IL-18, TNF-a and IFN-a⁄b, NK cell are
activated; whereas IL-4, IL-10 and TGF-b suppress NK
cell function. During malaria infections, and in response
to IL-12, NK cells are the first to secrete IFN-c (with cd
T cells and NK T cells responding later) and are able to
directly kill Pf-infected erythrocytes (81). Individual differ-
ences in NK responsiveness may lie in the underlying
human genome, such as functional allelic polymorphisms
in killer cell inhibitory receptors and toll-like receptors
(TLR) (82,83). Yet, embracing the complexity that consti-
tutes the human immune milieu, the recognition of IL-12
and IL-23 in orchestrating the development of TH1 and
TH17 subsets, respectively, pose new questions in T-cell
decision making [reviewed in (84)]. IL-12 and IL-23 are
two heterodimeric cytokines that share the p40 chain to
become biologically active. IL-12 and IL-23 are both
inhibited by IL-10, however DCs induced to differentiate
in the presence of prostaglandin E2 (PGE2) produce more
IL-23 than IL-12 (85). Interestingly, PGE2 has been shown
to inhibit INF-c production from na ve human cord blood
mononuclear cells (CBMCs) (86) and TD Ig production
by neonatal lymphocytes (87). PGE2 and IL-10 have been
implicated as mediators that bias foetal and neonatal
immunity away from excessive IFN-c production that
would be deleterious at the maternal–foetal interface (88).
The role for the IL-23⁄IL-17 axis in response to malaria
during infancy has yet to be explored.
The few studies directly investigating the impact of
malaria on human DC function have yielded conflicting
results. A recent balanced review attempts to resolves
these apparent contradictions concluding that disparate
findings could be explained by low-dose immune induc-
tion vs. high-dose immune suppression (89). The authors
suggest the dose-dependent DC response sequentially var-
ies during the course of an individual infection from
early, low-dose responsiveness to late, high-dose nonre-
sponsiveness. Dose-dependent DC responsiveness could
be extended to nonimmune infants, after prolonged peri-
ods of high malaria parasitemia, compared to semi-
immune adults who are able to restrict infections to lower
densities. However, this model does not take into account
that DC function is fundamentally impaired in neonates
and young children [reviewed in (64)] and that an increas-
ing body of research implicates impaired responses to
TLR ligands [reviewed in (88,90)] in poor infant immu-
nity to infectious diseases.
As priming the adaptive immune system appears to be
essential to inducing the desired response to a vaccine,
innate immune signatures and adjuvants are deservedly
earning more attention. Innate immune cells are activated
via TLRs that express pattern-recognition receptors used
to identify pathogen-associated molecular patterns. The
list of TLR ligands now includes malaria-derived mole-
cules: Pf toxin, glycosylphosphatidylinisitol is recognized
by TLR2 and TLR4, whereas parasite DNA complexed
with haemozoin is a TLR9 ligand (91–93). Interestingly,
TLR2 appears to be the key that preferentially induces
IL-23 expression in lieu of IL-12 (94). Recent studies have
evaluated TLR expression and responsiveness in humans
infected with malaria. Adults with severe and mild malaria
had increased expression of TLR2 and TLR4 on CD14
+
monocytes and myeloid DCs and decreased expression of
TLR9 on plasmacytoid DCs compared to adults with no
history of malaria exposure (95). Malaria-na ve adults
experimentally infected with Pf had increased expression
of TNF-a, IL-1b and IL-6 in response to a TLR4 ligand
(LPS) and IL-6 and IL-10 in response to TLR2 + TLR1
ligand (Pam3Cys) on day 8 of the infection (96). In vitro
peripheral blood mononuclear cell (PBMC) pre-incubation
experiments with Pf followed by TLR ligand stimulation
demonstrated a temporal-synergistic activation of TLR-4
and TLR-2 significantly increasing TNF-a and IFN-c but
reducing IL-10 production. This is a distinct contrast to
the effect observed when PMBCs are primed with LPS,
which induces subsequent TLR tolerance (97). Similarly,
naturally Pf-infected children had increased TLR2 expres-
sion on CD14
+ monocytes isolated from PBMCs com-
pared to uninfected children (aged 5–16 years old) and
enhanced TLR2 (Pam3Cys) activation but in this case
resulted in higher production of both IL-10 and TNF-a
(98). Consistent with a Pf-enhanced TLR responsiveness,
naturally ‘primed’ (in utero exposure) CBMCs produced
more IFN-c in response to both TLR3 (poly I : C) and
TLR4 (LPS) ligand stimulation if the mother was infected
with malaria during the last month of pregnancy, whereas
CBMCs without prenatal malaria exposure had signifi-
cantly higher TNF-a in response to the same ligands (99).
In this study, no differences were observed for IL-10 pro-
duction stimulated with TLR3 or TLR4 ligands and
maternal malaria history. This supports other neonatal
studies demonstrating differential effects of in utero Pf
exposure on adaptive immune responses to malaria (100).
Analogous to studies of adaptive immunity, seemingly
inconsistent results for innate immune responses appear
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as age and co-infections are not taken into account.
Clearly more studies are needed to fully appreciate the
synergy or antagonism of innate immune signals in
children compared to adults, and the impact of co-infec-
tions, when evaluating malaria vaccine efficacy.
MALARIA VACCINES EFFICACY IN CHILDREN
THUS FAR
For ethical reasons, malaria vaccines are tested for safety,
immunogenicity and efficacy in age de-escalating clinical tri-
als prior to reaching the ultimate target population: infants
<1 year of age. Therefore, deciding which vaccines are even-
tually tested in young children is determined by results gen-
erated from adult trials. Many malaria vaccine candidates
and adjuvant combinations have been tested in phase I and
II trials of adults with fewer reaching phase III trials in chil-
dren and fewer still with encouraging results [reviewed in
(101–103)]. Here, we describe two promising vaccine trials
conducted in young children: a pre-erythrocytic stage vac-
cine candidate, RTS,S that targets the CSP combined with
an adjuvant system AS01E; and a multi-valent blood stage
formulation, combination B comprised of MSP-1, MSP-2,
and ring-infected erythrocyte surface antigen (RESA) and
the adjuvant Montanide ISA 720.
The goal of RTS,S is to generate neutralizing humoral
immunity directed against the sporozoite stage of the
malaria parasite before they invade the liver, in addition
to inducing CSP-specific CD8 and CD4 Th1+ T cell
immunity. An RTS,S⁄AS01E efficacy trial was conducted
in Kenya and Tanzania from March through August 2007
in which children 5–17 months of age were randomly
assigned to receive either the malaria vaccine (n = 402) or
the control rabies vaccine (n = 407). The cumulative
8-month incidence of all clinical malaria episodes was 9%
in the group that received RTS,S compared to 21% in the
control group, with an adjusted efficacy of 56% (95% CI:
31–72; P < 0.001) (104). Vaccine immunogenicity was
determined by measuring titres of anti-CSP antibodies by
standard enzyme-linked immunosorbent assay units (EU).
The majority of children in both arms of the study had
detectable low level anti-CSP antibody titres however the
children receiving RTS,S had significantly higher titres
3 months post-immunization compared to the rabies vac-
cine control group. These antibodies titres waned over the
subsequent months of follow-up, and there was no
evidence that higher titres were associated with greater
protection against clinical disease than lower titres. The
efficacy of RTS,S⁄AS01E was similar to the previous
year’s study with the AS02D adjuvant formulation in
2-month-old Tanzanian infants at 65.2% (95% CI:
20–84.7; P = 0.01) (105). Of note the geometric mean
anti-CSP titre in the 5-month-old children 3 months after
the first dose of RTS,S⁄AS02D was 69.5 EU⁄mL
compared to the slightly older children (5–17 months old)
who had anti-CSP antibody titres of 539.6 EU⁄mL
3 months after first dose of RTS,S⁄AS01E. These anti-
body titres were fivefold lower than baseline measurements
in semi-immune adults (106,107). The reason for improved
antibody titres in the older children may have been due to
the immunogenic superiority of AS01 compared to AS02
adjuvant formulations; however, age of administration
cannot be ruled out since direct comparisons between dif-
ferent adjuvants do not necessarily correspond to differ-
ences in antibody titres (108). Choice of adjuvant can
nonetheless significantly impact strength and duration of
IFN-c and IL-5 responses to RTS,S (108) that may fight
malaria independent of antibodies. Assessments of cell-
mediated immunity were not reported for these trials in
children, yet could have provided additional clues as to
how RTS,S mediates protection and why higher antibody
titres were not predictive. Combination B, composed of
malaria blood stage proteins to MSP-1, MPS-2 and RESA
aimed to generate humoral as well as IFN-c mediated
immunity. This vaccine was tested in children 5–9 years
old living in Papua New Guinea and included measure-
ments of antibody titres and cytokines levels (i.e. IFN-c,
TNF-a, IL-4 and IL-10) (109). This study also assessed
the influence of clearing pre-existing malaria infections on
the development of immunity and controlling parasite
densities. Genton et al. found that antibody levels to all
three antigens were increased by the vaccine but only
MSP-1 induced IFN-c recall responses (which may have
been due to how this vaccine was constructed as it was
fused with a universal T-cell epitope derived from CSP).
The vaccine did not induce IL-10 or TNF-a however IL-4
levels were lower in response to MSP-1 though not to
MSP-2 or RESA. Clearing circulating malaria parasites
prior to immunization appeared deleterious for inducing
MSP1-specific IFN-c responses; perhaps by preventing
‘boosting’ afforded by natural infections. This vaccine
reduced parasite density (only in those not pretreated for
malaria infection) but did not reduce prevalence of infec-
tion and was strain-specific for MSP-2. Similar to RTS,S,
immunizing children with combination B failed to achieve
anti-malarial antibody levels observed in adults and titres
significantly waned over time.
MALARIA-EXPOSURE REDUCTION
PROGRAMMES
As malaria vaccine trials in infants provide optimism, pro-
gress has been made in decreasing the incidence of clinical
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sure-reduction programmes such as insecticide-treated bed-
nets (ITBN) and intermittent preventative therapy in
infants (IPTi). Both of these interventions decrease the
cumulative parasite burden by preventing some (but not
all) malaria infections, with the latter also decreasing the
duration of asymptomatic infections experienced by a
child (110). It is important to note that these interventions
are malaria-disease prevention measures targeting young
children and pregnant women, with most of the children
typically in good health and not experiencing symptoms
of malaria – and thus good candidates to participate in
malaria vaccine studies.
Monitoring the impact of these strategies on decreasing
the incidence of clinical and severe malaria has yielded
some interesting findings that are relevant to understand-
ing the development of anti-malarial immunity in infants
and young children. Several studies have addressed the
possibility that exposure-reduction programmes could
result in a delay in acquisition of immunity thereby shift-
ing clinical sequelae to an older age group – referred to
as a rebound effect. Evidence from ITBN studies has
alleviated this concern as bednets appear to mediate
reductions in malaria-associated morbidity by decreasing
parasite densities and delaying median age of first para-
sitaemia from 4 to 10 months of age (111). Even though
ITBN coverage reduced IgG antibody responses to pre-
erythrocytic antigens, there was no apparent difference in
IgG antibody levels to blood stage antigens in children
<2 years of age (112). Equally, studies examining the
impact of varying IPTi schedules on the development of
clinical immunity demonstrated a decrease in the inci-
dence of severe malaria during the first year of life and a
delay in time to first infection on an average of 2 months
(113). Decreases in clinical malaria were consistently
observed regardless of anti-malarial prophylaxis frequency
(e.g. weekly compared to three times within the first
12 months of life) (113–116). However, there was an
increase in the incidence of severe malaria observed dur-
ing the second year of life in children who received con-
tinuous, weekly chemoprophylaxis during their first year
of life compared to the placebo group (115,117). The
authors concluded that malarial anaemia was a function
of the age at which infection takes place (i.e. <1 year of
age) lending support to the hypothesis that intrinsic path-
ophysiological mechanism are involved in risk of severe
malaria. This observation could also implicate maternal
antibody protection as being important for the develop-
ment of infant immunity by providing a ‘buffer’ during
an infant’s first exposure to malaria and thereby attenu-
ating pathologic antigen stimulation. This clinical
rebound effect was no longer apparent once the children
reached 4 years of age and has been abrogated by follow-
ing a less intense prophylactic treatment schedule (i.e.
three times, at 3, 4 and 9 months of age in conjunction
with the Expanded Program on Immunization) (114).
A parallel assessment of humoral immune responses
within the context of a three-dose IPTi schedule was con-
ducted in the study by Quelhas et al. (113). Antibody lev-
els in those who were given IPTi did not significantly
differ compared to placebo controls, suggesting that IPTi
did not delay acquisition of humoral immunity. However,
differences were observed for those given IPTi who also
had at least one episode of clinical malaria (i.e. fever)
compared to those experiencing clinical malaria without
chemoprophylaxis. For children experiencing a febrile
malaria episode, those on ITPi generated higher antibody
levels for MSP-119 (3D7) and AMA-1 (3D7) compared to
placebos starting at 9 months of age, the point at which
maternal antibodies are waning and infant immunity
develops (113). This scenario hints at two possible mecha-
nisms. First, a moderate or limited antigen dose, resulting
from the prophylactic anti-malarial administration, may
be more permissive for inducing a robust antibody titre
compared to a higher antigen dose. Second, children given
IPTi resulting in less chronic asymptomatic malaria infec-
tions were more likely to generate higher antibody titres
when they experienced a febrile malaria episode, support-
ing a pivotal role for innate immune mediators in priming
anti-malarial immunity. These studies support the notion
that in addition to extrinsic factors that may modulate the
dose and duration of the infection there is an age-depen-
dent physiologic component involved in the development
and maintenance of functional immunity that is not well
understood. Interplay between exposure-reduction inter-
ventions and the development and maintenance of protec-
tive immunity to malaria in children is just beginning to
be explored. Thus, a child’s participation in an integrated
malaria prevention program may actually improve the
development of anti-malarial immunity.
AW A YF O R W A R D
The most evident impediment against basic immunologic
investigations of infants and young children are limited
blood volumes, an acceptable frequency of repeat sample
collections, and gaining ethical and parental approval for
enrolling often healthy children in research studies. Unfor-
tunately, these understandable obstacles have left children,
who are the most vulnerable to the adverse consequences
of malaria, understudied. In the midst of technological
advancements and ethical deliberations, some of these
long-standing issues are being overcome. Yet, if a malaria
vaccine is deemed efficacious in adults the question
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children. Current opinion in the field of immunology is
that the next generation of vaccines will need to be
designed to do what nature does not in order to confer
long-lasting protective immunity. With the ultimate goal
of designing a malaria vaccine that will be delivered
within the first year of life, when there appear to be
inherent down-regulatory mechanisms preventing the
induction and maintenance of protective immunologic
memory, the composition of such a vaccine may need to
differ from one that would protect an adult. It may not
be enough to teach an infant immune system to behave
like an adult’s by priming and boosting a pro-inflamma-
tory response against an array of malaria antigens that in
turn induce potent humoral immunity. A malaria vaccine
for infants may also need to be designed to subsequently
mute pro-inflammatory responses and further guide the
selection of the appropriate T and B cells to be main-
tained as memory – a ‘prime-boost-mute-select’ vaccine
design, if you will. Therefore, increasing our understand-
ing of basic immunologic differences between adults and
young children will provide the mechanistic insights
necessary to design a malaria vaccine that will be safe
and successful in infants.
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